Kornimate/medical-research-clean huggingface dataset:
brain effects of memory training in early psychosis

Conditions: Psychotic Disorders

Summary: background: people with psychosis show profound deficits in memory. a new cognitive remediation therapy using an app on a computer or mobile phone to improve memory has been effective in this population, but the neurobiological effects are unknown. objectives: 1) to use functional magnetic resonance imaging (fmri) to examine brain changes during a working memory task before and after a 12 hour memory training intervention on a computer or mobile phone, 2) to use diffusion tensor imaging (dti) to examine white matter connecting prefrontal and parietal lobe before and after training. methods: 46 people with psychosis will be randomized to a computerized training of either memory training or a control condition of non-memory games (language/card games) and will self-administer 4 hours of training over 4 days per week, for 3 weeks (12 hours total). memory training will be done with the peak app http://www.peak.net. imaging data will be gathered with a 3 tesla scanner pre and post training.


Eligibility criteria:
inclusion criteria: 1. male or female and between the ages of 18 and 40 2. able to understand and sign an informed consent document in english. 3. meet diagnostic criteria for schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or psychosis not otherwise specified. exclusion criteria: 1. impaired intellectual functioning (full-scale iq\<70). 2. past or current history of a clinically significant central nervous system disorder that may contribute to psychotic symptoms or confound their assessment. 3. current severe substance use disorder.
ozonized in-office and domiciliary gels vs chlorhexidine gel 1% for the management of peri-implant mucositis sites

Conditions: Peri-implant Mucositis

Summary: this is a split-mouth randomized controlled clinical trial (rct). after signing the informed consent, patients satisfying the inclusion criteria will undergo supragingival and subgingival professional oral hygiene of both arches performed with ultrasonic instrumentation with peek inserts, manual instrumentation with titanium curettes and air polishing with glycine powder. after that, the following treatment will be randomly assigned: * ozoral pro and ozoral gel administration and home application for 2 peri-implant mucositis sites. * curasept chlorhexidine gel 1% administration and domiciliary application for 14 days for 2 peri-implant contralateral sites. the study will last 6 months. patients will be visited at: t0, after 1 month from t0 (t1), after 3 months (t2), after 6 months (t3). professional hygiene will be performed again at t2 and t3. at each recall session, the following periodontal clinical indices were collected using a probe on each peri-implant site: bop, gbi, conditions of the marginal mucosa (swelling and erythema), suppuration, migration of the marginal mucosa, pd, pi ,bs.

this is a split-mouth randomized controlled clinical trial (rct). 30 patients is expected to be enrolled. after signing the informed consent, patients satisfying the inclusion criteria will undergo supragingival and subgingival professional oral hygiene of both arches performed with ultrasonic instrumentation with peek inserts, manual instrumentation with titanium curettes and air polishing with glycine powder. after that, the following treatment will be randomly assigned: * ozoral pro and ozoral gel administration and home application for 2 peri-implant mucositis sites. * curasept chlorhexidine gel 1% administration and domiciliary application for 14 days for 2 peri-implant contralateral sites. the study will last 6 months. patients will be visited at: t0, after 1 month from t0 (t1), after 3 months (t2), and after 6 months (t3). at t2 and t3, professional hygiene will be performed again. at each recall session, the following periodontal clinical indices were collected using a probe on each peri-implant site: bop (bleeding on probing) and gbi (gingival bleeding index) conditions of the marginal mucosa (swelling and erythema) suppuration migration of the marginal mucosa pd (probing depth) pi (plaque index) bs (bleeding score)

Eligibility criteria:
inclusion criteria: * age 18-70 years * presence of 2 peri-implant mucositis sites per side (left and right) with pd \> 5 mm * no systemic, metabolic and autoimmune disease * compliant patients exclusion criteria: * neurologic, psychiatric and mental diseases * patients taking bisphosphonates in the last 12 months * patients taking antibiotics during the study * pregnant and breastfeeding women * patients undergoing anticancer treatment
study of safety and efficacy of my008211a in in patients with paroxysmal nocturnal hemoglobinuria (pnh)

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Summary: the main purpose of this study is to evaluate the efficacy of my008211a in adult patients with pnh, showing signs of active hemolysis.

the purpose of this study is to determine whether my008211a is efficacious and safe for the treatment of pnh patients who are naïve to complement inhibitor therapy, including anti-c5 antibody.

Eligibility criteria:
inclusion criteria: * male and female participants ≥ 18 years of age and bmi ≥ 18.0 kg/m2 with a diagnosis of pnh confirmed by high-sensitivity flow cytometry with clone size ≥ 10%. * mean hemoglobin level \<100 g/l. * ldh \> 1.5 x upper limit of normal (uln). * vaccination against neisseria meningitidis infection is required prior to the start of study treatment. if not received previously, vaccination against streptococcus pneumoniae and haemophilus influenzae infections should be given. exclusion criteria: * patients with reticulocytes \<100x10\^9/l; platelets \<30x10\^9/l; neutrophils \<0.5x10\^9/l. * were using a complement inhibitor before the first administration of my008211a tablets or had discontinued a previous complement inhibitor for less than five half-lives or 120 days, whichever was the longest. * history of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus. * known or suspected hereditary complement deficiency. * previous bone marrow or hematopoietic stem cell transplantation. * previous splenectomy. * a history of malignancy within 5 years before screening, except cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix.
facial palsy treatment

Conditions: Facial Palsy; Stroke Rehabilitation

Summary: the primary objective of the study is to investigate the most effective treatment modalities available to speech language pathologist as well as movement difference by comparing them.


Eligibility criteria:
inclusion criteria: * patients with 1st stroke * hemorrhagic stroke * ischemic stroke * right hemispheric stroke * left hemispheric stroke * normal cognitive skills (based on montreal cognitive assessment moca) * normal language (not aphasic) * normal swallowing exclusion criteria: * patients with bell's palsy * facial trauma * post otitis media surgeries * neoplasm, malignant or tumor cell invasion of facial nerve * cognitive impairment * patients with aphasia * patients on defibrillator cardiac devices * patients with pacemakers or any other type of cardiac devices * multiple strokes
hemodynamic and perfusion response to drotrecogin alfa (activated) in patients with septic shock

Conditions: Sepsis; Septic Shock

Summary: the study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving drotrecogin alfa (activated).


Eligibility criteria:
inclusion: * 18 years of age or older with a diagnosis of septic shock * presence of a pulmonary artery catheter (or central venous catheters) * requiring vasopressor support despite adequate fluid resuscitation * an intravenous steroid administered for septic shock, except for those patients who were tested and are responders to a corticotropin stimulation test, or patients who do not receive a steroid due to the clinical judgment of the treating physician, based on an alternate assessment (e.g. normal baseline cortisol). exclusion: * onset of first-sepsis induced organ dysfunction is greater than 24 hours from the time of informed consent * baseline measurements of pulmonary artery occlusive pressure (paop) \< 12 mmhg or a central venous pressure (cvp) \< 8 mmhg * patient requires continuous oxygen therapy by face-mask * the presence of an advanced directive to withhold life-sustaining treatment, with the exception of a directive to withhold chest compressions only * have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry * weight \> 200 kg * are moribund (not expected to survive 24 hours) * are pregnant or are lactating and the milk is to be ingested by the infant (pregnancy status must be verified by urine or serum testing) * have not completed written informed consent signed by the patient or the patient's legal representative.
evaluation of u-akipredtm for predicting aki in critically ill patients within 12 hours: a multicenter prospective cohort study

Conditions: External Effectiveness Validation of Model

Summary: the goal of our study is to evaluate u-akipredtm for predicting aki in critically ill patients within 12 h by the multicenter prospective cohorts. aki was diagnosed by kidney disease improving global outcomes (kdigo) criteria. we designed five aspects including the overall fitting effecience evaluation, calibration curve, quantifying calibration performance, quantifying discrimination performance, quantifying clinical utility to evaluate the external validation model.


Eligibility criteria:
inclusion criteria: * critically ill patients who stayed in icu for over 24 h; * patients older than 18 years of age. exclusion criteria: * patients who admitted in icu had been diagnosed acute kidney injury; * patients who admitted in icu had been diagnosed acute kidney disease; * patients who admitted in icu had been diagnosed chronic kidney disease; * patients who admitted in icu had performed kidney dialysis; * patients who admitted in icu had performed kidney transplantation; * pregnant women.
detection dogs as a help in the detection of covid-19

Conditions: COVID-19

Summary: canine olfactive detection has proven its efficacy in numerous situations (explosives, drugs, bank notes...) including for early diagnosis of human diseases: various cancers, alert of diabetic or epileptic people in immediate alarm of crisis.

fighting such a viral outbreak requires a widespread testing, one of the key measures for tackling the pandemic. in june 2020, facing a decline of covid-19, it is possible to say that countries that have mastered their outbreak, and were able to maintain the number of infected people low, need to perform fewer test to correctly monitor the outbreak, than those countries where the virus has spread more widely. and for the same reasons, the timing of testing is also crucial. a high rate of testing will be way more effective to slow an outbreak if conducted earlier on, at a time when there is fewer infectious the aim of this study is to evaluate if the sweat produced by covid-19 persons (sars-cov-2 pcr positive) has a different odour for trained detection dogs than the sweat produced by non covid-19 persons. the study was conducted on 3 sites, following the same protocol procedures, and involved a total of 18 dogs. a total of 198 armpits sweat samples were obtained from different hospitals. for each involved dog, the acquisition of the specific odour of covid-19 sweat samples required from one to four hours, with an amount of positive samples sniffing ranging from four to ten.

Eligibility criteria:
inclusion criteria: * due to have a coronavirus swab test in the previous 24 hours * aged ≥ 18 years * suspected mild covid-19 symptoms or have been exposed to covid-19 * written informed consent provided exclusion criteria: * aged \< 18 years * written informed consent not provided * unable or unwilling to put a compresses for at least 4 h

Keywords: biomedical detection dogs; olfaction; olfactory sense; screening method; sniffer dogs
the caregiver's burden in cerebral palsy

Conditions: Cerebral Palsy

Summary: cerebral palsy (cp) results from damage to the developing brain of the fetus or infant. these non-progressive lesions cause a set of permanent movement and posture disorders, responsible for activity limitations. these disorders are often accompanied by sensory, perceptual, cognitive impairments, communication and behavioral disorders, and sometimes epilepsy and/or secondary musculoskeletal problems. it is the leading cause of motor disability in childhood and affects 200 newborns per year in belgium. cerebral palsy affects two to three people in every 1,000 of the world's population. the prevalence, incidence and most common causes have varied over time due to significant changes in obstetric care and pediatric care. in 75% of all cases of cerebral palsy, the lesions occurred before childbirth. the population of adults diagnosed with cerebral palsy is increasing as the survival rate of children born with a disability increases. this population requires adapted and expert care services for the continuous monitoring and management of their condition. in addition, the development of additional health problems in adulthood increases the need for permanent access to care structures. adults with cp have a higher rate of chronic health problems (ischemic heart disease) and a deterioration in their functional status. they would also have difficulty having a social and professional life which negatively impacts their quality of life. a large number of adults with cp cannot access appropriate care or medico-social structures. this results in a significant involvement of caregivers (family environment or close entourage). the role of caregiver is at the origin of a significant physical and psychological burden, whether for underage patients or adult patients. the study of this burden is well known in certain neurological pathologies (head trauma, multiple sclerosis, brain tumors). in the field of cerebral palsy, a study showed that the primary caregivers of children with cp had higher levels of psychological and physical disorders than the control group studied (caregivers of healthy children). currently, there are very few studies assessing the burden of caregivers of adults with cerebral palsy. the objective of this study is to analyze, through various specific questionnaires, the quality of life and the presence of depressive symptoms linked to the burden of caregivers of adults and children with cerebral palsy, taking into account socio-economic and environmental data.


Eligibility criteria:
inclusion criteria: - healthy subjects, aged 18 to 75, caring for relatives of adults and children with cerebral palsy, with a good understanding of the french language. exclusion criteria: - subjects under 18 or over 75, presenting a language barrier (interview guide written in french), subjects with a known history of psychiatric pathologies.
switching medication to treat schizophrenia

Conditions: Schizophrenia

Summary: this study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.

over the past several years, new, "atypical" antipsychotic medications have become available to treat schizophrenia with little information to guide prescribing for relatively stable outpatients. participants will be randomly assigned to either continue taking their current medications for schizophrenia, or to switch to a new medication. participants assigned to switch to a new medication will begin receiving either olanzapine (zyprexa), risperidone (risperdal), ziprasidone (geodon), quetiapine (seroquel), or aripiprazole (abilify), depending on what they are currently taking. participants currently taking a single oral medication will switch to olanzapine, risperidone, ziprasidone, quetiapine, or aripiprazole. participants currently taking a single conventional injectable will begin taking long-acting injectable risperidone (risperdal consta). participants currently taking two antipsychotic medications will begin taking only one of the medications they are currently using. participants will stay on their assigned treatment for 6 months, after which time the participant's prescribing psychiatrist will advise the participant on which medication should be used. study participants are interviewed at study start and at follow-up visits for 1 year.

Eligibility criteria:
inclusion criteria: * scid diagnosis of schizophrenia or schizoaffective disorder * partially remitted outpatients, defined as persons who have received clear symptomatic benefit from antipsychotic medication but remain symptomatic (due to lack of efficacy or inability to tolerate an efficacious dose) or suffer significant side effects * treatment with antipsychotic medications for at least 2 months * received at least 1 outpatient mental health service every 3 months for the past 6 months exclusion criteria: * severe symptoms or side effects that indicate the necessity for a medication change * currently taking 3 or more antipsychotic medications for ongoing daily administration (prn medications and mood stabilizers are allowable) * treatment with clozapine * one or more nights spent in a psychiatric hospitalization within the past 3 months * received services from a crisis intervention program within the past 3 months * require placement in a skilled nursing facility as a result of a physical condition or disability * criminal charges pending (once charges clear, the person will be considered) * pregnant or breast feeding * contraindication to any of the medications to which the patient might be assigned
analgesic effect of quadratus lumborum block application after laparoscopic cholecystectomy surgery

Conditions: Cholecystectomy; Postoperative Pain; Nerve Block

Summary: laparoscopy is frequently used today for intraabdominal operations. laparoscopic procedure has become the treatment of choice for many patients with symptomatic cholelithiasis. patients undergoing laparoscopic cholecystectomy suffer from acute postoperative pain, despite a multimodal analgesic regime. this is a randomised controlled trial efficay of the quadratus lumborum (ql) block in terms of analgesic efficacy in patients who undergo laparoscopic cholecystectomy.


Eligibility criteria:
inclusion criteria: -patients who were in the american society of anesthesiologists (asa) i-iii class and underwent laparoscopic cholecystectomy exclusion criteria: * previous history of opioid use preoperatively, * allergy to local anesthetics, * the presence of any systemic infection, * uncontrolled arterial hypertension, * uncontrolled diabetes mellitus.
outcomes of geriatric hip fractures in assiut university hospital

Conditions: Hip Fractures

Summary: hip fractures are common problem specially in elderly population the incidence is increasing nowadays because of increased incidence of motor vehicle accidents

hip fractures are a common problem specially in elderly population the incidence is increasing nowadays because of increased incidence of motor vehicle accidents the incidence of morbidity and mortality is increasing today and the mortality rate is about 30% the aim of the study is follow up of the patients aged 65 years and older who experienced hip fractures for one year to evaluate the outcome of different ways of intervention in elderly population.

Eligibility criteria:
inclusion criteria: * patients aged 65 years and older * with fractures acetabulum , neck of femur , trochanteric , subtrochanteric and reverse trochanteric fractures exclusion criteria: * no patient will be excluded
rahelp.org: an online self management program for adults with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the objective of this study is to determine the effects of an arthritis self-management program and an online support community delivered via an encrypted, secure web site on psychological well-being, pain, quality of life, global health status, and social supporting in adults with ra.

arthritis is the leading cause of disability in the united states. more than 7 million persons in this country report limitations in their daily activities due to arthritis. rheumatoid arthritis alone affects 1 of every 100 persons in the us. clinic-based self-management programs have been found to be effective in reducing both pain and disability for persons with ra. however, barriers to participation exist such as distance, time, limited transportation, and declining functional status. the internet is widely used as a source of information about health issues and may provide an opportunity to reduce these barriers and extend consumer access to self-management approaches. it is necessary to determine the efficacy of internet-delivered self-management programs.

Eligibility criteria:
inclusion criteria: * 18 or more years of age * rheumatoid arthritis diagnosed by a rheumatologist * stable medication regimen for 3 months exclusion criteria: * previous exposure to arthritis self-management programs * uncontrolled psychiatric comorbidity * uncontrolled medical comorbidity (e.g. active cancer)

Keywords: rheumatoid arthritis self-management internet